New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
07:40 EDTRPTPRaptor receives cysteamine bitartrate orphan drug designation from EC
Raptor Pharmaceutical announced that the European Commission approved its application for orphan drug designation of cysteamine bitartrate, the active ingredient in RP103, for the treatment of Huntington's disease. The decision follows a positive recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency in June. In February of this year, Raptor announced "encouraging top line" results from a planned 18-month analysis of the blinded, randomized, placebo-controlled phase of its ongoing CYST-HD clinical trial of RP103 in patients with early-stage Huntington's disease. Raptor submitted the 18-month CYST-HD results as part of the orphan application.
News For RPTP From The Last 14 Days
Check below for free stories on RPTP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
08:58 EDTRPTPRaptor Pharma should be owned ahead of potential catalysts, says JMP Securities
JMP Securities believes that Raptor has a number of potentially transformative upcoming catalysts. The firm thinks that adoption of the company's Proscybi drug could be a number of times higher than current levels, and it thinks that data due to be released over the next several months could be transformative for the company. The firm reiterates a $33 price target and Outperform rating.
September 11, 2014
09:38 EDTRPTPRaptor Pharmaceuticals management to meet with JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use